An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models

TIGIT (T-cell immunoglobulin and ITIM domain) has emerged as a promising target in cancer immunotherapy. It is an immune “checkpoint” inhibitor primarily expressed on activated T cells, NK cells and Tregs. Engagement of TIGIT to its ligands PVR and PVR-L2 leads to inhibitory signaling in T cells, pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xin, Xue, Liu, Ding, Xiao, Zhang, Jing, Jiang, Lei, Liu, Sha, Hou, Hongjia, Jiang, Bin, Cheng, Liang, Zhu, Qing, Zhang, Lijie, Zhou, Xiaosui, Ma, Jie, Liu, Qi, Li, Yucheng, Ren, Zhiying, Jiang, Beibei, Song, Xiaomin, Song, Jing, Jin, Wei, Wei, Min, Shen, Zhirong, Liu, Xuesong, Wang, Lai, Li, Kang, Zhang, Tong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902820/
https://www.ncbi.nlm.nih.gov/pubmed/35273608
http://dx.doi.org/10.3389/fimmu.2022.828319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902820/
https://www.ncbi.nlm.nih.gov/pubmed/35273608
http://dx.doi.org/10.3389/fimmu.2022.828319

Ejemplares similares